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Persistent dry cough is an occasional but clinically important adverse reaction to angiotensin I-converting enzyme
(ACE) inhibitors (ACEI). Its reported incidence is variable, and why cough occurs in only certain individuals has
been unclear. An insertion/deletion (I/D) polymorphism of the ACE gene is associated with serum ACE activity.
We have previously shown that susceptibility to cough induced by ACEI is associated with this polymorphism such
that patients with genotype II are more susceptible to cough than patients with other genotypes. In order to confirm
and extend our previous observation, we conducted a randomized, placebo-controlled, double-blind, cross-over
study in 10 healthy volunteers with genotype II and 10 with genotype DD. The cough threshold was determined by
the concentration of inhaled capsaicin causing two or more coughs. After the usage of an ACEI, cilazapril, for 4
weeks, changes in the cough threshold in subjects with genotype II [before: 6?6+3?7 nM (mean+SD); after: 5?0+
4?6 nM] significantly differed from those in subjects with genotype DD (before: 9?0+9?4 nM; after: 9?3+9?1 nM).
Skin responses to intradermal bradykinin, which is a substrate of ACE and tussigenic, were significantly increased
in subjects with genotype II (before: 1?6+0?6 vs. after: 2?6+0?5 cm2, P50?05) but not in subjects with genotype
DD (before: 1?4+0?5 vs. after: 1?6+0?6 cm2, n.s.) after usage of cilazapril. By contrast, skin responses to
intradermal substance P did not change in subjects with either genotype. These findings provide further evidence of
a link between ACEI-induced cough and I/D polymorphism of the ACE gene and suggest that ACEIs induce cough
by modulating the tissue level of bradykinin.
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Cough accompanied by an increased sensitivity of the
cough reflex is the most common symptom of inflammatory
airway diseases. Susceptibility to cough is also frequently
reported in patients receiving angiotensin I-converting
enzyme (ACE) inhibitors (ACEI) for treatment of hyper-
tension and/or heart failure (1–3). Because cough is usually
unresponsive to treatment, ACEI treatment can become
intolerable for some patients. Why only certain patients are
affected by this unique side-effect remains unclear.
Several mechanisms have been postulated for ACEI-
induced cough, but none adequately explains the phenom-
enon. Bradykinin and substance P, both of which are
degraded by ACE, have been suggested to cause sensitiza-
tion of airway sensory nerves and enhance the occurrenceReceived 31 January 2000 and accepted in revised form 25 October
2000.
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0954-6111/01/020130+06 $35?00/0of cough (4–10). The inflammatory skin and mucous
membrane reactions elicited by ACEIs, such as rash and
angioedema, are rare but potentially life-threatening. These
adverse tissue reactions may also be mediated by kinins,
since the wheal responses to intra-dermal bradykinin and
substance P have been demonstrated to be potentiated by
treatment with ACEIs (11,12). Thus, cough and angio-
edema are likely to have common causative mediators
whose levels are regulated by tissue activity of ACE.
Rigat et al. have described an insertion/deletion (I/D)
polymorphism of the human ACE gene, which consists of
the presence or absence of a 287 base pair (bp) insert in
intron 16 on chromosome 17q23 (13). The most notable
and clinically relevant phenomenon is that this polymorph-
ism of the ACE gene is associated with inter-individual
variations in serum ACE activity, which is high in
genotypes II, ID and DD, in increasing order (13,14). This
fact indicates that catalytic rates of mediators responsible
for cough are also high in this order, and thus that I/D
polymorphism of ACE may affect the occurrence rate of
ACEI-induced cough. Indeed, we have previously reported
that the genetic susceptibility to cough induced by ACEIs in
patients with hypertension and/or heart failure may be# 2001 HARCOURT PUBLISHERS LTD
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type II being most susceptible to cough (15).
To prospectively examine the association between the
occurrence of ACEI-induced cough and I/D polymorphism
of the ACE gene, we measured cough threshold as
determined by inhalation of capsaicin, a relatively specific
C-fibre stimulant, before and after administration of an
ACEI, cilazapril, and investigated the relation between
changes in the threshold and the gene polymorphism in
healthy volunteers. We also examined dermal response to
bradykinin and substance P in an attempt to estimate ACE
activity in the tissue.
Subjects and methods
SUBJECTS
Twenty healthy female subjects without any lung and
airway disease were selected so as to provide equal numbers
of the two genotypes, i.e. n¼10 for each of the genotypes
DD [age, 19?3+0?9 (SD) years] and II (19?6+0?7 years).
Since women have been reported to be more susceptible to
cough induced by ACEI (4), we selected only female
volunteers, expecting more occurrence of cough in the
present study. All were non-smokers and normotensive.
They gave written informed consent to participate in the
study, which was approved by the Medical Ethics
Committee of the School of Medicine, Hokkaido Uni-
versity.
DETERMINATION OF ACE GENOTYPE
Genomic DNA was purified from peripheral blood
leukocytes by the use of an extraction kit (SepaGene;
Sanko Junyaku Co. Ltd., Tokyo, Japan). A 287-bp I/D
polymorphism in intron 16 of the ACE gene was identified
by polymerase chain reaction (PCR) as described pre-
viously (16). Briefly, two primers, sense oligo 5’-CTGGA-
GACCACTCCCATCCTTTCT-3’ and anti-sense oligo 5’-
GATGTGGCCATCACATTCGTCAGAT-3’, were syn-
thesized to amplify the polymorphic fragment. Reactions
were performed with 10 pmol of each primer in a final
volume of 50l containing 100 ng of genomic DNA, 3mM
MgCl2, 50mM KCl, 10mM Tris-HCl, pH 8?4, 0?1mgml
71
gelatin, 0?5mM of each dNTP, and 1 unit of Taq
polymerase (Perkin Elmer Cetus, Norwalk, CT, U.S.A.).
The DNA was amplified for 30 cycles. The PCR products
were electrophoresed in 4% agarose gel and visualized by
ethidium bromide staining.
STUDY PROTOCOL
The present study was conducted in a randomized, placebo-
controlled, double-blind, cross-over fashion. Randomiza-
tion was performed by one of the investigators, and
capsaicin challenge tests and skin tests were performed by
the others. Placebo containing exact exipients of cilazapril
tablets (InhibaceTM) were prepared at the PharmaceuticalDivision of Hokkaido University Hospital. Each subject
received oral doses of 1mg cilazapril and matched placebo
daily for 4 weeks in a random order on two separate
occasions with a washout period of 2 weeks between each
administration period. The capsaicin challenges were
performed before and 2 h after dosing on the first and the
last day of each administration period. Study subjects took
no other medication for the duration of the study.
CAPSAICIN CHALLENGE TESTS
Cough challenge testing with inhaled capsaicin was
performed as previously described (2). Capsaicin (Boehrin-
ger Ingelheim Bioproducts Partnership, Heidelberg, Ger-
many) was dissolved in ethanol and diluted in saline in
doses of 0?0, 0?1, 0?2, 0?4, 0?8, 1?6, 3?2, 6?4, 12?8, 25?6, and
51?2 nM. The subjects wore a nose clip and inhaled single
breaths of aerosol generated by a nebulizer (Model 646;
DeVilbiss Health Care Inc., Somerset, PA, U.S.A.) in
incremental doses starting from pure saline (0.0 nM of
capsaicin) with a 5-min interval between doses. The number
of coughs occurring during a 5-min interval after each dose
was recorded. The concentration of capsaicin causing two
or more coughs was taken as the cough threshold (17).
SKIN REACTION
Skin responses were examined in nine subjects with
genotype II and nine with DD. Two injection sites were
marked on the volar aspect of the dominant forearm, and
0?1ml of saline containing 10mgml71 bradykinin (BA-
CHEM Feinchemikalien AG, Bubendorf, Switzerland) or
0?1mgml71 substance P (BACHEM Feinchemikalien AG)
was administered intradermally. Skin responses were
photographed after 15 min and quantified as the wheal
area outlined in the photos. A digital computer and NIH
image (Wayne Rasband Analytics, NIH, MD, U.S.A.) were
used to calculate the wheal area.
MEASUREMENT OF ACE ACTIVITY,
BRADYKININ AND SUBSTANCE P
Serum ACE activities were measured by colorimetric assay
(ACE Color; Fujirebio Inc., Tokyo, Japan) (18). Plasma
bradykinin (19) and substance P (20) were determined by
radioimmunoassay. All samples were stored at7708C until
the assay was performed.
STATISTICAL ANALYSIS
Data are presented as mean+SD. The changes between
values before and after the usage of cilazapril or placebo in
different genotypes were compared by a two-way analysis
of variance (ANOVA) with one between-subject factor (i.e.
factor ‘genotype’) and one within-subject factor (i.e. factor
‘time’: repeated measurements before and after the usage of
cilazapril or placebo in the same study subjects) or with two
within-subject factors (i.e. factors ‘time’ and ‘period’). We
132 T. TAKAHASHI ET AL.compared serum ACE activities and skin responses before
and after the administration of cilazapril or placebo by the
Student’s paired t-test. The Student’s unpaired t-test was
used to assess difference in baseline serum ACE levels or
cough thresholds between subjects with the genotype II and
those with DD. Statistical analyses were performed using
the SPSS statistical package (SPSS, Chicago, IL, U.S.A.).
Differences with a P-value less than 0?05 were considered
significant.
Results
All subjects completed the study. Each subject recorded
symptoms in a ‘symptom diary’. None developed cough
throughout the study period. After the administration of
cilazapril, serum ACE activities were effectively reduced in
all subjects, and an interaction between genotypes and
changes in ACE activities during the cilazapril period was
significant by a two-way ANOVA (Fig. 1). ACE activities
after the use of cilazapril were significantly decreased
compared with those before the use of cilazapril by the
Student’s paired t-test both in subjects with genotype II
(before: 11?1+3?7 vs. after: 3?8+4?1 IU l71, P50?01) and
those with DD (before: 17?0+2?3 vs. after: 3?2+3?5 IU l71,
P50?01). An interaction between genotypes and changes in
ACE activities during the placebo period was not sig-
nificant by a two-way ANOVA (genotype II, before:
12?0+4?3 vs. after: 11?9+4?7 IU l71; genotype DD, before:
18?5+3?2 vs. after: 16?8+2?1 IU l71).
Cough could be induced by the inhalation of increasing
concentrations of capsaicin in all subjects. There was no
significant difference in changes of the cough threshold
during the placebo period between subjects with genotype
II and those with genotype DD by a two-way ANOVAFIG. 1. Serum ACE activity before and after the
administration of cilazapril according to genotypes of the
ACE gene. Results are reported as mean+SD for 10
subjects of each genotype. A significant difference between
before and after administration of cilazapril is indicated
by *P50?01. Significant difference between genotype DD
and II before administration of cilazapril is indicated by
{P50?01.(genotype II, before: 6?2+3?9 vs. after: 6?0+4?2 nM;
genotype DD, 5?3+2?4 vs. 6?6+3?7 nM). After the admin-
istration of cilazapril for 4 weeks, changes in the cough
threshold in subjects with genotype II significantly differed
from those in subjects with genotype DD (genotype II,
before: 6?6+3?7 vs. after: 5?0+4?6 nM; genotype DD,
before: 9?0+9?4 vs. after: 11?5+10?1 nM, P50?05) by the
same statistical method (Fig. 2). However, when time (i.e.
before or after the use of either cilazapril or placebo) and
periods (i.e. placebo or cilazapril period) were included as
two within-subject factors, interaction between these two
factors was not significant in subjects with either genotype
II or genotype DD. Thus, changes in the cough threshold
during cilazapril period did not significantly differ from
those in the placebo period for either genotype.
Changes in skin responses to intra-dermal bradykinin
during cilazapril period in subjects with genotype II
significantly differed from those in subjects with genotype
DD by a two-way ANOVA (Fig. 3). Skin responses to
bradykinin in subjects with genotype II were significantly
increased after the use of cilazapril (before: 1?6+0?6 vs.
after: 2?6+0?5 cm2, P50?05) by the Student’s paired t-test,
whereas they did not change in subjects with genotype DD
(before: 1?4+0?5 vs. after: 1?6+0?6 cm2, n.s.) (Fig.3). Skin
responses to intra-dermal substance P during cilazapril
period did not significantly change in subjects with either
genotype II (before: 1?3+0?5 vs. after: 1?6+0?.8 cm2, n.s.)
or genotype DD (before: 1?0+0?5 vs. after: 1?1+0?5 cm2,
n.s.) (data not shown). We found no significant difference in
plasma levels of bradykinin and substance P before and
after the administration of cilazapril in subjects with either
genotype (data not shown).
Discussion
We have previously reported that the genetic susceptibility
to cough induced by ACEI in patients with hypertensionFIG. 2. Changes in cough threshold before and after the
usage of cilazapril for 4 weeks. Data are mean+SD. Open
symbols and closed symbols denote subjects with the
genotypes II and DD, respectively. *P50?05 by a two-
way ANOVA.
FIG. 3. Changes in skin responses to intra-dermal
bradykinin as expressed in wheal area, before and after
the usage of cilazapril for 4 weeks. Data are mean+SD.
Open symbols and closed symbols denote subjects with
the genotypes II and DD, respectively. *P50?05 by a
two-way ANOVA.
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with subjects having genotype II being most susceptible to
cough (15). In the present study, we attempted to re-
examine the idea that the ACE gene polymorphism may
represent a susceptibility mutation for ACEI-induced
cough by measuring cough threshold in healthy subjects.
Though a small number of subjects with either genotype
failed to develop an observable cough, we found that
changes in cough threshold were significantly different
between subjects with genotype II and those with genotype
DD after the administration of cilazapril. However, our
results only partly support our previous observation in a
clinic-based study, since changes in cough threshold during
the use of cilazapril in genotype II were not significantly
different from those during the placebo period. This was
probably caused by a weak statistical power.
The distinctly different effects of ACEI on the cough
threshold between the two genotypes may result from the
more intense suppression of ACE activities in genotype II.
However, serum ACE activities did not differ between
genotypes II and DD after the administration of cilazapril.
This was apparently due to high levels of residual ACEI in
the serum when ACE activities were assayed in vitro. The
airway tissue ACE activities are of critical importance in
determining a catabolic rate of mediators that can induce
cough by stimulating C fibres. In this respect, serum ACE
activities may not properly reflect ACE activities in the
perineuronal tissue. This may be the case specifically
following the administration of ACEI in as much as tissue
transition of ACEI is dicult to estimate. As a surrogate
measure of tissue ACE activities, wheal responses to intra-
dermal bradykinin and substance P, both of which are
substrates of ACE, have been used (11,12,21). Our results
showed that skin responses to bradykinin were increased insubjects with genotype II but not in those with genotype
DD after the administration of cilazapril. This result
indicates a significant decrease in tissue ACE activities in
subjects with a low basal ACE activity after the adminis-
tration of cilazapril and may explain why
cough threshold was decreased in those subjects. Mean-
while, the absence of a significant change in skin responses
to intra-dermal substance P may be due to a partial
dependency of this substrate on ACE as a catalytic enzyme,
since this substrate is also degraded by neutral endopepti-
dase (6).
Several mechanisms have been proposed to explain
ACEI-induced cough (9,22–25). Among candidate media-
tors, bradykinin has been strongly implicated in the
mechanism for the development of cough (21,26). However,
we were unable to detect any significant changes in plasma
levels of bradykinin following cilazapril usage, even in
subjects with genotype II. This observation seems to be
incompatible with our results on skin responses; however,
data on the effect of ACEI administration on blood
bradykinin levels are generally conflicting and inconclusive
(27). At therapeutic doses, plasma levels of ACEI are
usually not high enough to cause accumulation of circulat-
ing bradykinin (27,28), and thus our results are consistent
with several previous reports (28–30). An inability to
observe reduced circulating levels of a mediator by the
use of ACEI does not exclude the possibility that such a
mediator is actually involved in the mechanism of cough,
since it is the local rather than the circulating levels, which
have primary importance. Because tissue ACE activity is
most likely to be reduced after the administration of
cilazapril specifically in subjects with genotype II, the tissue
level of endogenous bradykinin may be conversely in-
creased, leading to bronchial irritability and cough in
susceptible subjects. Though direct evidence for such a
mechanism is lacking in the present study, the results of
skin responses support a possible role of bradykinin in
neurogenic inflammation in ACEI-induced cough.
There is evidence to suggest that the I/D polymorphism is
in strong linkage disequilibrium with a major gene effect at
the ACE gene locus, which controls up to 44% of the
variability in ACE levels (14). Over 70 polymorphisms have
recently been identified in the ACE gene (31,32) and some
of these polymorphisms remained significantly associated
with ACE levels (32). Other studies have suggested the
existence of a second functional locus possibly unlinked to
the ACE gene (33). The inability to replicate our observa-
tion (34,35) and the lack of significant linkage between I/D
polymorphism and ACEI-associated cough (36) may be
attributable to the polygenic nature of regulating ACE
levels or to racial differences.
In conclusion, this study has provided further evidence
for the involvement of ACE gene polymorphism and
ACEI-induced cough. It is likely that the polymorphism
affects the ACEI-induced cough via modulation of levels of
bradykinin. However, we cannot exclude possible roles of
other tussigenic mediators in view of the wide substrate
specificity of ACE, nor can we preclude the possibility that
a variant of other genes closely linked to the ACE gene
causes the observed association.
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